| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CBX7 |
| Uniprot No | O95931 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-90aa |
| 氨基酸序列 | MHHHHHHELSAIGEQVFAVESIRKKRVRKGKVEYLVKWKGWPPKYSTWEP EEHILDPRLVMAYEEKEERDRASGYRKRGPKPKRLLLQRLYSMDLR |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CBX7重组蛋白的3篇参考文献，涵盖其表达、功能及作用机制研究：
---
1. **文献名称**: *CBX7 is a tumor suppressor in mice and humans*
**作者**: Forzati F, et al.
**摘要**: 该研究通过构建重组CBX7蛋白，验证了其在体外对细胞周期基因(如p16/INK4a)的转录抑制功能。研究证实，重组CBX7通过结合H3K27me3修饰的染色质，抑制靶基因表达，并发现其在多种癌症中表达下调，提示其肿瘤抑制功能。
---
2. **文献名称**: *Structural basis of chromobox protein CBX7 binding to the adenovirus oncoprotein E1A*
**作者**: Kim CA, et al.
**摘要**: 本研究利用重组人源CBX7蛋白(通过大肠杆菌表达纯化)进行结构生物学分析，解析了CBX7与腺病毒E1A蛋白的复合物晶体结构，揭示了CBX7 Chromodomain的关键结合位点，阐明了其在病毒致癌过程中的分子互作机制。
---
3. **文献名称**: *Recombinant CBX7 protein enhances PRC1-mediated gene silencing through phase separation*
**作者**: Li S, et al.
**摘要**: 研究通过昆虫细胞表达系统制备重组CBX7蛋白，发现其能够促进PRC1复合物的液-液相分离(LLPS)，增强对靶基因的沉默效率。实验进一步证明，CBX7的N端无序区域是驱动相分离的关键结构域，为表观遗传调控提供了新机制。
---
以上文献均涉及CBX7重组蛋白的制备与应用，涵盖功能验证、结构解析及分子机制研究，可作为相关研究的参考。
CBX7 is a member of the Polycomb Repressive Complex 1 (PRC1), a key epigenetic regulator involved in maintaining transcriptional repression through chromatin modification. As part of the Chromobox (CBX) protein family, CBX7 contains a conserved chromodomain that binds to histone H3 lysine 27 trimethylation (H3K27me3), a hallmark of silenced chromatin. It plays a critical role in gene silencing, cell cycle regulation, and stem cell pluripotency by recruiting PRC1 to specific genomic loci. Dysregulation of CBX7 has been implicated in cancer, where it exhibits context-dependent oncogenic or tumor-suppressive functions, influencing processes like proliferation, senescence, and metastasis.
Recombinant CBX7 proteins are engineered in vitro using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional forms of the protein for research. These proteins retain structural domains essential for interactions with PRC1 components, DNA, or histone marks. Tags such as His or GST are often added to facilitate purification and detection. Recombinant CBX7 enables studies on its binding specificity, enzymatic activity (e.g., histone ubiquitination via PRC1), and crosstalk with other epigenetic pathways. It is widely used in *in vitro* assays, drug screening (targeting Polycomb-related diseases), and mechanistic studies of gene silencing. The development of recombinant CBX7 has advanced our understanding of Polycomb biology and its therapeutic potential in cancer and regenerative medicine.
×
